Jeffrey Kraws - Innovation1 Biotech CEO Director

IVBT Stock

USD 0 0.00 0.00%

Insider

Jeffrey Kraws is CEO Director of Innovation1 Biotech

Age	59
Phone	646-380-1923
Web	https://www.innovation1bio.com

Innovation1 Biotech Management Efficiency

The company has return on total asset (ROA) of (0.0781) % which means that it has lost $0.0781 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.789) %, meaning that it created substantial loss on money invested by shareholders. Innovation1 Biotech's management efficiency ratios could be used to measure how well Innovation1 Biotech manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Innovation1 Biotech to Peers

Predict price of Innovation1 Biotech

Innovation1 Biotech currently holds 554.4 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Innovation1 Biotech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Innovation1 Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Innovation1 Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovation1 Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovation1 to invest in growth at high rates of return. When we think about Innovation1 Biotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	MS BA	CSL Limited	53
	Damian Esq	Vertex Pharmaceuticals	48
	Christina Hickie	CSL Limited	N/A
	Monique Carter	Novo Nordisk AS	50
	Marcus Schindler	Novo Nordisk AS	59
	Mike Tirozzi	Vertex Pharmaceuticals	N/A
	Martin Lange	Novo Nordisk AS	53
	Monique Carter	Novo Nordisk AS	51
	MS BA	CSL	53
	Wilfried Freudenberg	CSL Limited	N/A
	Henrik Poulsen	Novo Nordisk AS	53
	Lars Jorgensen	Novo Nordisk AS	57
	Wilfried Freudenberg	CSL	N/A
	BS BS	CSL	61
	Douglas Langa	Novo Nordisk AS	57
	BCom BComm	CSL	57
	Marcus Schindler	Novo Nordisk AS	57
	Ourania Tatsis	Vertex Pharmaceuticals	53
	Kristen Ambrose	Vertex Pharmaceuticals	47
	BS BS	CSL Limited	61
	Paul BA	CSL Limited	66

Innovation1 Biotech Inc. operates as a small molecule drug discovery company. The company was founded in 2014 and is based in New York, New York. Innovation1 Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people. Innovation1 Biotech [IVBT] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

	Return On Equity	-1.79
	Return On Asset	-0.0781

Innovation1 Biotech Leadership Team

Elected by the shareholders, the Innovation1 Biotech's board of directors comprises two types of representatives: Innovation1 Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Innovation1. The board's role is to monitor Innovation1 Biotech's management team and ensure that shareholders' interests are well served. Innovation1 Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Innovation1 Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Tammy Phillips, Managing Director
	Jeffrey Kraws, CEO Director

Innovation1 Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Innovation1 Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-1.79
	Return On Asset	-0.0781
	Current Valuation	1.83 M
	Shares Outstanding	20.02 M
	Shares Owned By Insiders	74.66 %
	Price To Earning	0.01 X
	Price To Book	0.05 X
	Gross Profit	(17 K)
	EBITDA	(38.33 M)
	Net Income	(40.88 M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Innovation1 OTC Stock Analysis

When running Innovation1 Biotech's price analysis, check to measure Innovation1 Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovation1 Biotech is operating at the current time. Most of Innovation1 Biotech's value examination focuses on studying past and present price action to predict the probability of Innovation1 Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovation1 Biotech's price. Additionally, you may evaluate how the addition of Innovation1 Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC